Comparison · NCT00127530-a634bf40
Fampridine-SR vs Placebo- Sugar Pill: Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Fampridine-SR vs Placebo- Sugar Pill: Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk). Trial comparisons, record NCT00127530-a634bf40. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00127530-a634bf40
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.348 | 0.289 | 0.413 | wilson | |
| Risk in group 2 | 0.0833 | 0.0388 | 0.17 | wilson | |
| Risk difference, group 1 minus group 2 | 0.265 | 0.16 | 0.343 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 4.18 | 1.9 | 9.18 | log | |
| Odds ratio, group 1 over group 2 | 5.88 | 2.44 | 14.2 | log | |
| Number needed to treat, for one more participant with the outcome on Fampridine-SR than on Placebo- Sugar Pill | 3.78 | 2.91 | 6.26 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Fampridine-SR | 10 milligram (mg) tablet twice a day (b.i.d.) | 78 | 224 | OG001 |
| Group 2 | Placebo- Sugar Pill | Placebo control group | 6 | 72 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk)
- Description
- Patients who showed a faster walking speed for at least three of the four on-drug visits during the double-blind treatment period as compared to the maximum speed for any of the five off-drug visits.
- Time frame
- Days 14, 42, 70 and 98 of treatment, corresponding to the four on-drug visits during double-blind treatment period.
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- Study of Oral Fampridine-SR in Multiple Sclerosis
- NCT number
- NCT00127530
- Phases
- PHASE3
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR, Placebo
- Lead sponsor
- Acorda Therapeutics
- Results first posted
- 2011-05-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00127530?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00127530-a634bf40